These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 34196111)

  • 21. Alternative Weighting Approaches for Anchored Matching-Adjusted Indirect Comparisons via a Common Comparator.
    Petto H; Kadziola Z; Brnabic A; Saure D; Belger M
    Value Health; 2019 Jan; 22(1):85-91. PubMed ID: 30661638
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Validating the Assumptions of Population Adjustment: Application of Multilevel Network Meta-regression to a Network of Treatments for Plaque Psoriasis.
    Phillippo DM; Dias S; Ades AE; Belger M; Brnabic A; Saure D; Schymura Y; Welton NJ
    Med Decis Making; 2023 Jan; 43(1):53-67. PubMed ID: 35997006
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Indirect Treatment Comparison of Inotuzumab Ozogamicin Versus Blinatumomab for Relapsed or Refractory Acute Lymphoblastic Leukemia.
    Proskorovsky I; Su Y; Fahrbach K; Vandendries E; Pagé V; Onyekwere U; Wang Y; Cappelleri JC; Stelljes M
    Adv Ther; 2019 Aug; 36(8):2147-2160. PubMed ID: 31140123
    [TBL] [Abstract][Full Text] [Related]  

  • 24. On the double-robustness and semiparametric efficiency of matching-adjusted indirect comparisons.
    Cheng D; Tchetgen ET; Signorovitch J
    Res Synth Methods; 2023 May; 14(3):438-442. PubMed ID: 36537355
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Indirect comparison of the antiviral efficacy of peginterferon alpha 2a plus ribavirin used with or without simeprevir in genotype 4 hepatitis C virus infection, where common comparator study arms are lacking: a special application of the matching adjusted indirect comparison methodology.
    Van Sanden S; Pisini M; Duchesne I; Mehnert A; Belsey J
    Curr Med Res Opin; 2016; 32(1):147-54. PubMed ID: 26455472
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Indirect comparisons of competing interventions.
    Glenny AM; Altman DG; Song F; Sakarovitch C; Deeks JJ; D'Amico R; Bradburn M; Eastwood AJ;
    Health Technol Assess; 2005 Jul; 9(26):1-134, iii-iv. PubMed ID: 16014203
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma.
    Kelley RK; Mollon P; Blanc JF; Daniele B; Yau T; Cheng AL; Valcheva V; Marteau F; Guerra I; Abou-Alfa GK
    Adv Ther; 2020 Jun; 37(6):2678-2695. PubMed ID: 32424805
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Using audit information to adjust parameter estimates for data errors in clinical trials.
    Shepherd BE; Shaw PA; Dodd LE
    Clin Trials; 2012 Dec; 9(6):721-9. PubMed ID: 22848072
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Comparison of Relative-Efficacy Estimate(S) Derived From Both Matching-Adjusted Indirect Comparisons and Standard Anchored Indirect Treatment Comparisons: A Review of Matching-Adjusted Indirect Comparisons.
    Cassidy O; Harte M; Trela-Larsen L; Walsh C; White A; McCullagh L; Leahy J
    Value Health; 2023 Nov; 26(11):1665-1674. PubMed ID: 37460009
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessing the impact of a matching-adjusted indirect comparison in a Bayesian network meta-analysis.
    Leahy J; Walsh C
    Res Synth Methods; 2019 Dec; 10(4):546-568. PubMed ID: 31368653
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Perils of Randomized Controlled Trial Survival Extrapolation Assuming Treatment Effect Waning: Why the Distinction Between Marginal and Conditional Estimates Matters.
    Jennings AC; Rutherford MJ; Latimer NR; Sweeting MJ; Lambert PC
    Value Health; 2024 Mar; 27(3):347-355. PubMed ID: 38154594
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adjustment for baseline characteristics in randomized trials using logistic regression: sample-based model versus true model.
    Perneger T; Combescure C; Poncet A
    Trials; 2023 Feb; 24(1):107. PubMed ID: 36782238
    [TBL] [Abstract][Full Text] [Related]  

  • 34. How large are the consequences of covariate imbalance in cluster randomized trials: a simulation study with a continuous outcome and a binary covariate at the cluster level.
    Moerbeek M; van Schie S
    BMC Med Res Methodol; 2016 Jul; 16():79. PubMed ID: 27401771
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The importance of considering differences in study and patient characteristics before undertaking indirect treatment comparisons: a case study of siponimod for secondary progressive multiple sclerosis.
    Samjoo IA; Worthington E; Haltner A; Cameron C; Nicholas R; Dahlke F; Adlard N
    Curr Med Res Opin; 2020 Jul; 36(7):1145-1156. PubMed ID: 32216597
    [No Abstract]   [Full Text] [Related]  

  • 36. Estimating the comparative efficacy of cladribine tablets versus alternative disease modifying treatments in active relapsing-remitting multiple sclerosis: adjusting for patient characteristics using meta-regression and matching-adjusted indirect treatment comparison approaches.
    Berardi A; Siddiqui MK; Treharne C; Harty G; Wong SL
    Curr Med Res Opin; 2019 Aug; 35(8):1371-1378. PubMed ID: 30786783
    [No Abstract]   [Full Text] [Related]  

  • 37. A comparison of meta-methods for synthesizing indirect effects.
    van Zundert CHJ; Miočević M
    Res Synth Methods; 2020 Nov; 11(6):849-865. PubMed ID: 32833348
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Matching-adjusted indirect comparison of benralizumab
    Bourdin A; Husereau D; Molinari N; Golam S; Siddiqui MK; Lindner L; Xu X
    Eur Respir J; 2018 Nov; 52(5):. PubMed ID: 30309978
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Model-based standardization using multiple imputation.
    Remiro-Azócar A; Heath A; Baio G
    BMC Med Res Methodol; 2024 Feb; 24(1):32. PubMed ID: 38341552
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Assessment-Schedule Matching in Unanchored Indirect Treatment Comparisons of Progression-Free Survival in Cancer Studies.
    Kapetanakis V; Prawitz T; Schlichting M; Ishak KJ; Phatak H; Kearney M; Stevens JW; Benedict A; Bharmal M
    Pharmacoeconomics; 2019 Dec; 37(12):1537-1551. PubMed ID: 31555968
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.